Evaluation of CRP/Albumin Ratio in Polycystic Ovarian Syndrome

Introduction: Polycystic Ovarian Syndrome (PCOS), an endocrine disorder that disproportionately affects reproductive-aged women, causes hormonal imbalance, metabolic dysfunction, and persistent low-grade inflammation. Since inflammation is fundamental to polycystic ovarian syndrome (PCOS), indicators including C-reactive protein (CRP) and albumin are used to assess inflammation. The CRP/Albumin ratio is a new indication of diet-systemic inflammation relationship. The major goal of this study was to establish the clinical relevance of the CRP/Albumin ratio in PCOS patients. Objective: The study aimed to compare PCOS-diagnosed women’s CRP/Albumin ratio to healthy controls. One secondary purpose was to determine if CRP/Albumin correlated with other clinical factors including insulin resistance and BMI. Materials and Methods: At Patna Medical College and Hospital, 200 women with PCOS were recruited from June 2023 to May 2024 a retrospective cross-sectional study. Clinical data like CRP and albumin were collected from medical records. Participants were 18–40-year-old women with Rotterdam-diagnosed polycystic ovary syndrome (PCOS). Patient exclusion criteria included pregnancy, other inflammatory disorders, and recent infections. For biochemical and demographic data, we used descriptive statistics, and for CRP/Albumin ratio and other clinical variable patterns, we used correlation analysis. We used SPSS for statistical analysis. Results: The study found that PCOS patients had higher CRP levels (7.8 ± 3.5 mg/L) than controls (2.2 ± 1.0 mg/L) but lower albumin levels (4.1 ± 0.5 g/dL vs. 4.5 ± 0.4 g/dL). In PCOS patients, the average CRP/Albumin ratio was 1.9, significantly greater than the control group’s 0.5 ratio (p < 0.001). Insulin resistance, BMI, and CRP/Albumin ratio were strongly linked (r = 0.38, p < 0.001). Conclusion: The elevated CRP/Albumin ratio suggests ongoing low-grade inflammation in polycystic ovary syndrome (PCOS) patients. This ratio can identify patients at risk for metabolic issues like insulin resistance and cardiovascular disease and assess polycystic ovary syndrome (PCOS) inflammation. This ratio may monitor therapy response, but further research is needed to determine its clinical usefulness in PCOS diagnosis and management.